5 results on '"Mitra, Debarpan"'
Search Results
2. Fabrication of a New Coumarin Based Fluorescent "turn-on" Probe for Distinct and Sequential Recognition of Al3+ and F− Along With Its Application in Live Cell Imaging.
- Author
-
Maji, Atanu, Naskar, Rahul, Mitra, Debarpan, Gharami, Saswati, Murmu, Nabendu, and Mondal, Tapan Kumar
- Subjects
BINDING constant ,DETECTION limit ,ALUMINUM foam ,CANCER cells ,BREAST cancer ,BREAST imaging - Abstract
A new coumarin based fluorescent switch PCEH is fabricated which displays high selective sensing towards Al
3+ among other metal cations at physiological pH. On gradual addition of Al3+ , PCEH shows a brilliant "turn-on" emission enhancement in MeOH/H2 O (4/1, v/v) solution. This new fluorescent switch is proven to be a reversible probe by gradual addition of F− into the PCEH-Al3+ solution. Detection limit as well as binding constant values are calculated to be in the order of 10–9 M and 104 M−1 respectively. We have also explored its potential as a biomarker in the application of live cell imaging using breast cancer cells (MDA-MB-231 cell). [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. Prediction of anticancer drug response in an adjuvant clinical setting for breast cancers by ex vivo live tumor phenotypic assay platform.
- Author
-
Nath, Partha, Murmu, Nabendu, Mitra, Debarpan, Oliyarashi, Muthusami, Rajappa, Manoj, Mehrotra, Debapriya Ghosh, Radhakrishnan, Padhma, Thiyagarajan, Saravanan, Majumder, Biswanath, and Majhi, Tapas
- Subjects
ANTINEOPLASTIC agents ,BREAST cancer ,PROPHECY ,TECHNICAL reports ,GROWTH factors - Abstract
Basis: Our learning from the limited trajectory of biomarker guided and genomic assay based response prediction to inform clinical action ability of cancers led to the strategic rethinking of developing and validating robust and individualized platform (CANScript) that make prediction based on multiple phenotypic inputs. Methods: Accelerated CANScript Enabled Personalized Treatment (ACCEPT) is an investigator initiated study aiming to predict response to anticancer drugs at clinic. Surgically resected tumors from primary breast cancer patients (n=30) were cultured in slices and treated with Epirubicin, Cyclophosphamide and 5FU in CANScript platform for three days in presence of autologous growth factors, immune milieu and indication specific matrix support where patient tumor microenvironment was extensively preserved. The outcome was measured by integrating both pathological (tumor content, viability, proliferation and induction of apoptosis) and kinetic endpoints (cell viability and metabolism) into a single data trained M score algorithm as described (Majumder B et al., Nature Commun, 2015, Brijwani N et al., Scientific Reports, 2017). After 6 cycles of therapy, following surgery, patients were clinically evaluated for response based on multiple criteria including radiological examination. This short-term clinical response was compared with CANScript driven response prediction. Results: Out of 25 evaluable patients, outcome is available for ten patients (40%) till today. Data indicate that CANScript derived predictive scores for responders and non-responders were highly correlated with clinical observation. For all six clinical non-responders, CANScript guided outcome was found to be matched with clinical outcome. Similarly, for rest 4 patients, while CANScript predicted response, 3 patients showed clinical response. These preliminary data from an ongoing study are encouraging and more patients will be enrolled and follow up data will be collected. Conclusion: Phenotypic assay based platform technologies are emerging as a new frontier of individual response prediction based on the complex and dynamic interplay of tumor and stroma including immune network. CANScript guided prediction of response showed encouraging results to understand the response of drugs at clinic, would offer further opportunity to incorporate phenotypic inputs for informed treatment decision in an adjuvant setting. [ABSTRACT FROM AUTHOR]
- Published
- 2017
4. Prediction Of Anticancer Drug Response In An Adjuvant Clinical Setting For Breast Cancers By Ex Vivo Live Tumor Phenotypic Assay Platform.
- Author
-
Murmu, Nabendu, Mitra, Debarpan, and Oliyarashi, Muthusami
- Subjects
- *
ANTINEOPLASTIC agents , *BREAST cancer , *PROPHECY , *TECHNICAL reports , *GROWTH factors - Abstract
Basis: Our learning from the limited trajectory of biomarker guided and genomic assay based response prediction to inform clinical action ability of cancers led to the strategic rethinking of developing and validating robust and individualized platform (CANScript) that make prediction based on multiple phenotypic inputs. Methods: Accelerated CANScript Enabled Personalized Treatment (ACCEPT) is an investigator initiated study aiming to predict response to anticancer drugs at clinic. Surgically resected tumors from primary breast cancer patients (n=30) were cultured in slices and treated with Epirubicin, Cyclophosphamide and 5FU in CANScript platform for three days in presence of autologous growth factors, immune milieu and indication specific matrix support where patient tumor microenvironment was extensively preserved. The outcome was measured by integrating both pathological (tumor content, viability, proliferation and induction of apoptosis) and kinetic endpoints (cell viability and metabolism) into a single data trained M score algorithm as described (Majumder B et al., Nature Commun, 2015, Brijwani N et al., Scientific Reports, 2017). After 6 cycles of therapy, following surgery, patients were clinically evaluated for response based on multiple criteria including radiological examination. This short-term clinical response was compared with CANScript driven response prediction. Results: Out of 25 evaluable patients, outcome is available for ten patients (40%) till today. Data indicate that CANScript derived predictive scores for responders and non-responders were highly correlated with clinical observation. For all six clinical non-responders, CANScript guided outcome was found to be matched with clinical outcome. Similarly, for rest 4 patients, while CANScript predicted response, 3 patients showed clinical response. These preliminary data from an ongoing study are encouraging and more patients will be enrolled and follow up data will be collected. Conclusion: Phenotypic assay based platform technologies are emerging as a new frontier of individual response prediction based on the complex and dynamic interplay of tumor and stroma including immune network. CANScript guided prediction of response showed encouraging results to understand the response of drugs at clinic, would offer further opportunity to incorporate phenotypic inputs for informed treatment decision in an adjuvant setting. [ABSTRACT FROM AUTHOR]
- Published
- 2017
5. Hypericum roeperianum bark extract suppresses breast cancer proliferation via induction of apoptosis, downregulation of PI3K/Akt/mTOR signaling cascade and reversal of EMT.
- Author
-
Guefack, Michel-Gael F., Talukdar, Debojit, Mukherjee, Rimi, Guha, Subhabrata, Mitra, Debarpan, Saha, Depanwita, Das, Gaurav, Damen, François, Kuete, Victor, and Murmu, Nabendu
- Subjects
- *
WOUND healing , *FLOW cytometry , *IN vitro studies , *BIOLOGICAL models , *IN vivo studies , *ANIMAL experimentation , *COLONY-forming units assay , *WESTERN immunoblotting , *ANTINEOPLASTIC agents , *APOPTOSIS , *HYPERICUM perforatum , *MITOCHONDRIA , *CELLULAR signal transduction , *EPITHELIAL-mesenchymal transition , *CELL survival , *CELL motility , *CELL cycle , *BARK , *CELL proliferation , *TRANSFERASES , *PLANT extracts , *POLYMERASE chain reaction , *DNA damage , *TRANSCRIPTION factors , *BREAST tumors , *MICE , *PHARMACODYNAMICS - Abstract
Hypericum roeperianum is a medicinal spice traditionally used in West Africa to treat female sterility, fungal infections, and cancer. It has previously been reported that H. roeperianum exhibits cytotoxic potential by reducing the viability of cancer cells involving multidrug-resistant phenotypes, but its underlying molecular mechanism remains unknown. The mechanistic involvement of H. roeperianum methanolic crude extract (HRC) in attenuating breast cancer progression by exploring the effects on mitochondrial apoptosis and epithelial-mesenchymal transition (EMT) was investigated. In the present study, we examined the anticancer properties of HRC through MTT assay, colony formation, wound healing assay, spheroid formation, DNA fragmentation and flow cytometry for cell cycle arrest, apoptosis (Annexin V/PI staining) and mitochondrial membrane potential (MMP) (JC-1) detection. In addition, western blot analysis of various proteins and quantitative real time PCR of various genes involved in apoptosis, EMT and the PI3K/Akt/mToR signal transduction pathway were performed. This study revealed that HRC treatment significantly decreased breast cancer cell viability, colony forming efficiency and reduced the ability of cell migration and spheroid formation. HRC also induced apoptosis in MDA-MB-231 and MCF-7 via promoting G0/G1 cell cycle arrest, disruption of mitochondrial membrane potential and induction of DNA damage. The crude extract induced apoptosis by activating the intrinsic pathway with a stronger effect that relies on the combined potency of associated molecular markers including Bax, Bad, Bcl-2, cytochrome C, caspase-9, and cleaved-PARP. It was also found that HRC regulates the PI3K/Akt/mToR pathway. In addition, HRC inhibited EMT by expressional alteration of Vimentin and E-cadherin, as well as the regulatory transcription factors such as Snail and Slug. The in vitro findings reflected similar mechanistic approach in 4T1 cell induced syngeneic mice model, indicating the reduction of tumor volume along with the significant expressional alteration of EMT and apoptotic markers. Taken together the findings concluded that H. roeperianum is a potential source of cytotoxic phytochemicals that exhibit abortifacient effect on breast cancer, both in vitro and in vivo , thus could further be utilized in breast cancer therapy. [Display omitted] • The anticancer mechanism of action of Hypericum roeperianum crude extract (HRC) was evaluated. • HRC also induced apoptosis in MDA-MB-231 and MCF-7. • HRC causes G0/G1 cell cycle arrest, disruption of mitochondrial membrane potential and DNA damage. • HRC inhibited the epithelial-mesenchymal transition. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.